Iovance Biotherapeutics Updates Corporate Presentation with Key Financials and Pipeline Progress
Iovance Biotherapeutics (NASDAQ:IOVA) updated its corporate presentation, highlighting treatment of over 1,500 patients across more than 90 centers. The company reported $319 million in cash reserves providing a runway through 2028 and provided strong revenue guidance for the year.
Tickers: $IOVA
Topics: biopharmaceutical cell therapy revenue guidance TIL therapies